When differences in genetic variants are accounted for in clinical trial design, interventional trials can become much more successful for particular patient groups.. [
more ]
There is an increasing shift with pharma/biotech researchers and execs not just speaking about platforms and performance but also focusing more intently on people and impacts on daily lives.. [
more ]
Are price controls the best way to rein in drug costs, or do we perhaps need to dig deeper into the issue of what is required to bring drugs to market to begin with?.. [
more ]
